3 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 2 | Recruiting 2 |
Follow Tr1X, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| Treatment of Moderate to Severe Refractory Crohn's Disease TRX103, Cyclophosphamide - Crohns Disease | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2025-05-05 | 2025-12-10 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
Abdominal Pain (1) · Bronchiolitis Obliterans Syndrome (1) · Crohn Disease (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Leukemia, Myelomonocytic, Chronic (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Bendamustine Hydrochloride (1) · Cyclophosphamide (1)
United States (3)
Maria Grazia Roncarolo, MD (1)